Hailong Tao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hailong Tao has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Jiangtao Zhao
Department of Cardiology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
5 shared publicationsKui Zhu
Department of Cardiology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
4 shared publicationsXiaowei Chen
Department of Cardiology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
4 shared publicationsFen Qin
Department of Cardiology, the First affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
3 shared publications- Jianzeng Dong
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
3 shared publications - Bo-Wen Chen
Department of Cardiology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (38) , e50754
Statin use and 28-day survival in critically ill patients with non-acute myocardial infarction cardiogenic shock
Evidence regarding statin therapy in non-acute myocardial infarction cardiogenic shock is limited, and retrospective medication studies are vulnerable to treatment-timing bias. We examined whether the association between statin exposure and 28-day mortality persisted after accounting for the timing of statin administration. This retrospective cohort study used medical information mart for intensive care IV data from 991 adults with non-acute myocardial infarction cardiogenic shock. Statin exposure was ascertained from medication records that included atorvastatin and other statin agents. In the conventional time-fixed analysis, exposure was defined as receipt of any statin during the intensive care unit (ICU) stay. A 24-hour landmark analysis included patients alive at 24 hours, classified exposure according to statin administration during the 1st 24 hours, and began follow-up at the landmark. Separate 1:1 propensity-score matching (PSM) procedures and Cox models were performed for each exposure definition. Statin agent, 1st recorded dose, route, and time to 1st administration, together with specific mechanical-support, anti-inflammatory, and vasoactive co-treatments, were descriptively summarized in the matched cohorts. In the conventional cohort, 475 patients received a statin during the ICU stay and 516 did not; 255 patients per group remained after PSM. Conventional analyses suggested lower 28-day mortality before matching (adjusted hazard ratio [HR], 0.703; 95% confidence interval [CI], 0.539–0.918; P = .010) and after PSM (adjusted HR, 0.709; 95% CI, 0.507–0.993; P = .045). In the 24-hour landmark cohort, 311 patients received a statin within 24 hours and 680 did not; 255 patients per group remained after PSM. The association was absent before matching (adjusted HR, 1.127; 95% CI, 0.854–1.487; P = .398) and after PSM (adjusted HR, 1.190; 95% CI, 0.833–1.701; P = .339). Atorvastatin was the predominant 1st statin in both matched exposed groups. In 4-category analyses, the apparent benefit among new initiators in conventional models disappeared after the 24-hour landmark definition was applied. The apparent survival advantage associated with conventional time-fixed statin exposure was not reproduced after treatment timing was addressed. These findings do not support an independent 28-day survival benefit from statin administration within the 1st 24 hours of ICU admission and highlight the potential influence of immortal-time, treatment-selection, and co-treatment biases.
- 18 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (38) , e50754
Open AccessStatin use and 28-day survival in critically ill patients with non-acute myocardial infarction cardiogenic shock
Evidence regarding statin therapy in non-acute myocardial infarction cardiogenic shock is limited, and retrospective medication studies are vulnerable to treatment-timing bias. We examined whether the association between statin exposure and 28-day mortality persisted after accounting for the timing of statin administration. This retrospective cohort study used medical information mart for intensive care IV data from 991 adults with non-acute myocardial infarction cardiogenic shock. Statin exposure was ascertained from medication records that included atorvastatin and other statin agents. In the conventional time-fixed analysis, exposure was defined as receipt of any statin during the intensive care unit (ICU) stay. A 24-hour landmark analysis included patients alive at 24 hours, classified exposure according to statin administration during the 1st 24 hours, and began follow-up at the landmark. Separate 1:1 propensity-score matching (PSM) procedures and Cox models were performed for each exposure definition. Statin agent, 1st recorded dose, route, and time to 1st administration, together with specific mechanical-support, anti-inflammatory, and vasoactive co-treatments, were descriptively summarized in the matched cohorts. In the conventional cohort, 475 patients received a statin during the ICU stay and 516 did not; 255 patients per group remained after PSM. Conventional analyses suggested lower 28-day mortality before matching (adjusted hazard ratio [HR], 0.703; 95% confidence interval [CI], 0.539–0.918; P = .010) and after PSM (adjusted HR, 0.709; 95% CI, 0.507–0.993; P = .045). In the 24-hour landmark cohort, 311 patients received a statin within 24 hours and 680 did not; 255 patients per group remained after PSM. The association was absent before matching (adjusted HR, 1.127; 95% CI, 0.854–1.487; P = .398) and after PSM (adjusted HR, 1.190; 95% CI, 0.833–1.701; P = .339). Atorvastatin was the predominant 1st statin in both matched exposed groups. In 4-category analyses, the apparent benefit among new initiators in conventional models disappeared after the 24-hour landmark definition was applied. The apparent survival advantage associated with conventional time-fixed statin exposure was not reproduced after treatment timing was addressed. These findings do not support an independent 28-day survival benefit from statin administration within the 1st 24 hours of ICU admission and highlight the potential influence of immortal-time, treatment-selection, and co-treatment biases.
- 13 March 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (6)
USP10 Deubiquitinates MTX2 to Suppress cGAS-STING Signaling in MI
BACKGROUND: Myocardial infarction (MI) results in 3 distinct regions within the left ventricle: the infarct zone, the border zone (BZ), and the remote zone. A major focus of MI research is investigating the intrinsic mechanisms in the BZ to alleviate myocardial injury. USP10 (ubiquitin-specific peptidase 10) expression is reduced in BZ cardiomyocytes, indicating potential for targeted therapeutic intervention. METHODS: Isolated BZ cardiomyocytes and hypoxia-treated neonatal rat cardiomyocytes were used to investigate the expression of USP10 in MI. Cultured neonatal rat cardiomyocytes and genetically engineered mice were used to assess the importance of USP10 in the context of MI. Immunoprecipitation mass spectrometry and ubiquitination assays were used to explore the mechanisms by which USP10 suppresses the cGAS (cyclic GMP-AMP synthase) stimulator of interferon genes (STING) pathway. RESULTS: Our study reveals that USP10 is critical in protecting against cardiac injury following MI. Specifically, USP10 mitigates MI-induced mitochondrial dysfunction and prevents the release of mitochondrial DNA into the cytosol, thereby inhibiting the activation of the cGAS-STING signaling pathway. Additionally, USP10 deubiquitinates the K48-linked ubiquitination of MTX2 (metaxin 2), thus enhancing MTX2 protein stability. We identified K93 as a critical ubiquitination site on MTX2 through mutagenesis analysis. Importantly, our findings demonstrate that the MTX2-K93R mutation rectifies USP10 loss-induced exacerbation of MI. CONCLUSIONS: This study identifies USP10 as a novel regulator of the cGAS-STING signaling pathway in MI. Moreover, our findings demonstrate that a decrease in USP10 in the BZ cardiomyocytes can be therapeutically targeted to mitigate cardiac injury in MI.
- 13 March 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (6)
USP10 Deubiquitinates MTX2 to Suppress cGAS-STING Signaling in MI
BACKGROUND: Myocardial infarction (MI) results in 3 distinct regions within the left ventricle: the infarct zone, the border zone (BZ), and the remote zone. A major focus of MI research is investigating the intrinsic mechanisms in the BZ to alleviate myocardial injury. USP10 (ubiquitin-specific peptidase 10) expression is reduced in BZ cardiomyocytes, indicating potential for targeted therapeutic intervention. METHODS: Isolated BZ cardiomyocytes and hypoxia-treated neonatal rat cardiomyocytes were used to investigate the expression of USP10 in MI. Cultured neonatal rat cardiomyocytes and genetically engineered mice were used to assess the importance of USP10 in the context of MI. Immunoprecipitation mass spectrometry and ubiquitination assays were used to explore the mechanisms by which USP10 suppresses the cGAS (cyclic GMP-AMP synthase) stimulator of interferon genes (STING) pathway. RESULTS: Our study reveals that USP10 is critical in protecting against cardiac injury following MI. Specifically, USP10 mitigates MI-induced mitochondrial dysfunction and prevents the release of mitochondrial DNA into the cytosol, thereby inhibiting the activation of the cGAS-STING signaling pathway. Additionally, USP10 deubiquitinates the K48-linked ubiquitination of MTX2 (metaxin 2), thus enhancing MTX2 protein stability. We identified K93 as a critical ubiquitination site on MTX2 through mutagenesis analysis. Importantly, our findings demonstrate that the MTX2-K93R mutation rectifies USP10 loss-induced exacerbation of MI. CONCLUSIONS: This study identifies USP10 as a novel regulator of the cGAS-STING signaling pathway in MI. Moreover, our findings demonstrate that a decrease in USP10 in the BZ cardiomyocytes can be therapeutically targeted to mitigate cardiac injury in MI.
- 31 January 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 211, 106320
Development of an interpretable machine learning model for predicting 4-year chronic kidney disease risk in elderly hypertensive patients
- 31 January 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 211, 106320
Development of an interpretable machine learning model for predicting 4-year chronic kidney disease risk in elderly hypertensive patients
- Open Access
- 1 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Predictive utility of systemic inflammatory response index and pan-immune-inflammatory value in assessing myocardial infarction risk among cases with unstable angina
This study aimed to explore the predictive value of the systemic inflammatory response index (SIRI) and the pan-immune-inflammatory value (PIV) in assessing the risk of myocardial infarction (MI) among UA cases. The risk factors were identified by univariate and binary logistic regression analyses, and the relationship between variables was analyzed using Pearson correlation analysis. The receiver operating characteristic (ROC) curve analysis was used to assess the predictive value of the indicators for MI in UA cases. No significant difference was found in gender, age, hypertension, body mass index (BMI), diabetes, alcohol consumption, smoking status, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or hemoglobin (Hb) between the two groups (P > 0.05). Nevertheless, statistical differences were found in monocyte (MON), N-terminal pro-B-type natriuretic peptide (NT-proBNP), platelet count (PLT), lymphocyte count (LYM), neutrophil count (NEU), SIRI, and PIV (P < 0.05). Pearson correlation analysis indicated positive correlations between SIRI and PIV (r = 0.807), SIRI and NT-proBNP (r = 0.116), and PIV and NT-proBNP (r = 0.176) (all P < 0.05). Binary logistic regression analysis identified NT-proBNP, SIRI, and PIV as significant predictors of MI in UA cases (P < 0.05). ROC curve analysis demonstrated that SIRI achieved an area under the curve (AUC) of 0.851 (standard error (SE) = 0.027, 95% confidence interval (CI): 0.798–0.904), and the Youden index was 0.58 (specificity, 74.58%; sensitivity, 83.83%). PIV yielded an AUC of 0.902 (SE = 0.020, 95% CI: 0.863–0.940), and the Youden index was 0.68 (specificity, 80.97%; sensitivity, 86.76%). The united SIRI + PIV model yielded an AUC of 0.920 (SE = 0.016, 95% CI: 0.889–0.951), and the Youden index was 0.71 (specificity, 79.93%; sensitivity, 91.18%). Applying the optimal cutoff thresholds, the incidence of MI was lower in cases with SIRI ≤ 1.23 compared to SIRI > 1.23, and it was also found in cases with PIV ≤ 215.88 compared to PIV > 215.88 (P < 0.05). SIRI and PIV were found highly effective in predicting MI risk in UA cases, and their combination could further enhance the predictive performance.
- 1 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Open AccessPredictive utility of systemic inflammatory response index and pan-immune-inflammatory value in assessing myocardial infarction risk among cases with unstable angina
This study aimed to explore the predictive value of the systemic inflammatory response index (SIRI) and the pan-immune-inflammatory value (PIV) in assessing the risk of myocardial infarction (MI) among UA cases. The risk factors were identified by univariate and binary logistic regression analyses, and the relationship between variables was analyzed using Pearson correlation analysis. The receiver operating characteristic (ROC) curve analysis was used to assess the predictive value of the indicators for MI in UA cases. No significant difference was found in gender, age, hypertension, body mass index (BMI), diabetes, alcohol consumption, smoking status, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or hemoglobin (Hb) between the two groups (P > 0.05). Nevertheless, statistical differences were found in monocyte (MON), N-terminal pro-B-type natriuretic peptide (NT-proBNP), platelet count (PLT), lymphocyte count (LYM), neutrophil count (NEU), SIRI, and PIV (P < 0.05). Pearson correlation analysis indicated positive correlations between SIRI and PIV (r = 0.807), SIRI and NT-proBNP (r = 0.116), and PIV and NT-proBNP (r = 0.176) (all P < 0.05). Binary logistic regression analysis identified NT-proBNP, SIRI, and PIV as significant predictors of MI in UA cases (P < 0.05). ROC curve analysis demonstrated that SIRI achieved an area under the curve (AUC) of 0.851 (standard error (SE) = 0.027, 95% confidence interval (CI): 0.798–0.904), and the Youden index was 0.58 (specificity, 74.58%; sensitivity, 83.83%). PIV yielded an AUC of 0.902 (SE = 0.020, 95% CI: 0.863–0.940), and the Youden index was 0.68 (specificity, 80.97%; sensitivity, 86.76%). The united SIRI + PIV model yielded an AUC of 0.920 (SE = 0.016, 95% CI: 0.889–0.951), and the Youden index was 0.71 (specificity, 79.93%; sensitivity, 91.18%). Applying the optimal cutoff thresholds, the incidence of MI was lower in cases with SIRI ≤ 1.23 compared to SIRI > 1.23, and it was also found in cases with PIV ≤ 215.88 compared to PIV > 215.88 (P < 0.05). SIRI and PIV were found highly effective in predicting MI risk in UA cases, and their combination could further enhance the predictive performance.
- Open Access
- 18 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 183, 106554
UPLC-MS/MS analysis of Salvia miltiorrhiza Bge. Extract and its ameliorative effect of endothelial cell metabolism in isoproterenol-induced myocardial injury
- 18 April 2025
- Published by Elsevier in Fitoterapia
- Vol. 183, 106554
Open AccessUPLC-MS/MS analysis of Salvia miltiorrhiza Bge. Extract and its ameliorative effect of endothelial cell metabolism in isoproterenol-induced myocardial injury
- Open Access
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e033700
Low‐Dose Colchicine Ameliorates Doxorubicin Cardiotoxicity Via Promoting Autolysosome Degradation
Background: The only clinically approved drug that reduces doxorubicin cardiotoxicity is dexrazoxane, but its application is limited due to the risk of secondary malignancies. So, exploring alternative effective molecules to attenuate its cardiotoxicity is crucial. Colchicine is a safe and well‐tolerated drug that helps reduce the production of reactive oxygen species. High doses of colchicine have been reported to block the fusion of autophagosomes and lysosomes in cancer cells. However, the impact of colchicine on the autophagy activity within cardiomyocytes remains inadequately elucidated. Recent studies have highlighted the beneficial effects of colchicine on patients with pericarditis, postprocedural atrial fibrillation, and coronary artery disease. It remains ambiguous how colchicine regulates autophagic flux in doxorubicin‐induced heart failure. Methods and Results: Doxorubicin was administered to establish models of heart failure both in vivo and in vitro. Prior studies have reported that doxorubicin impeded the breakdown of autophagic vacuoles, resulting in damaged mitochondria and the accumulation of reactive oxygen species. Following the administration of a low dose of colchicine (0.1 mg/kg, daily), significant improvements were observed in heart function (left ventricular ejection fraction: doxorubicin group versus treatment group=43.75%±3.614% versus 57.07%±2.968%, P =0.0373). In terms of mechanism, a low dose of colchicine facilitated the degradation of autolysosomes, thereby mitigating doxorubicin‐induced cardiotoxicity. Conclusions: Our research has shown that a low dose of colchicine is pivotal in restoring the autophagy activity, thereby attenuating the cardiotoxicity induced by doxorubicin. Consequently, colchicine emerges as a promising therapeutic candidate to improve doxorubicin cardiotoxicity.
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e033700
Open AccessLow‐Dose Colchicine Ameliorates Doxorubicin Cardiotoxicity Via Promoting Autolysosome Degradation
Background: The only clinically approved drug that reduces doxorubicin cardiotoxicity is dexrazoxane, but its application is limited due to the risk of secondary malignancies. So, exploring alternative effective molecules to attenuate its cardiotoxicity is crucial. Colchicine is a safe and well‐tolerated drug that helps reduce the production of reactive oxygen species. High doses of colchicine have been reported to block the fusion of autophagosomes and lysosomes in cancer cells. However, the impact of colchicine on the autophagy activity within cardiomyocytes remains inadequately elucidated. Recent studies have highlighted the beneficial effects of colchicine on patients with pericarditis, postprocedural atrial fibrillation, and coronary artery disease. It remains ambiguous how colchicine regulates autophagic flux in doxorubicin‐induced heart failure. Methods and Results: Doxorubicin was administered to establish models of heart failure both in vivo and in vitro. Prior studies have reported that doxorubicin impeded the breakdown of autophagic vacuoles, resulting in damaged mitochondria and the accumulation of reactive oxygen species. Following the administration of a low dose of colchicine (0.1 mg/kg, daily), significant improvements were observed in heart function (left ventricular ejection fraction: doxorubicin group versus treatment group=43.75%±3.614% versus 57.07%±2.968%, P =0.0373). In terms of mechanism, a low dose of colchicine facilitated the degradation of autolysosomes, thereby mitigating doxorubicin‐induced cardiotoxicity. Conclusions: Our research has shown that a low dose of colchicine is pivotal in restoring the autophagy activity, thereby attenuating the cardiotoxicity induced by doxorubicin. Consequently, colchicine emerges as a promising therapeutic candidate to improve doxorubicin cardiotoxicity.
- 29 February 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (4) , 811-820
Data‐driven classification of left atrial morphology and its predictive impact on atrial fibrillation catheter ablation
Introduction: Various left atrial (LA) anatomical structures are correlated with postablative recurrence for atrial fibrillation (AF) patients. Comprehensively integrating anatomical structures, digitizing them, and implementing in‐depth analysis, which may supply new insights, are needed. Thus, we aim to establish an interpretable model to identify AF patients' phenotypes according to LA anatomical morphology, using machine learning techniques.Methods and Results: Five hundred and nine AF patients underwent first ablation treatment in three centers were included and were followed‐up for postablative recurrent atrial arrhythmias. Data from 369 patients were regarded as training set, while data from another 140 patients, collected from different centers, were used as validation set. We manually measured 57 morphological parameters on enhanced computed tomography with three‐dimensional reconstruction technique and implemented unsupervised learning accordingly. Three morphological groups were identified, with distinct prognosis according to Kaplan−Meier estimator (p < .001). Multivariable Cox model revealed that morphological grouping were independent predictors of 1‐year recurrence (Group 1: HR = 3.00, 95% CI: 1.51−5.95, p = .002; Group 2: HR = 4.68, 95% CI: 2.40−9.11, p < .001; Group 3 as reference). Furthermore, external validation consistently demonstrated our findings.Conclusions: Our study illustrated the feasibility of employing unsupervised learning for the classification of LA morphology. By utilizing morphological grouping, we can effectively identify individuals at different risks of postablative recurrence and thereby assist in clinical decision‐making.
- 29 February 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (4) , 811-820
Data‐driven classification of left atrial morphology and its predictive impact on atrial fibrillation catheter ablation
Introduction: Various left atrial (LA) anatomical structures are correlated with postablative recurrence for atrial fibrillation (AF) patients. Comprehensively integrating anatomical structures, digitizing them, and implementing in‐depth analysis, which may supply new insights, are needed. Thus, we aim to establish an interpretable model to identify AF patients' phenotypes according to LA anatomical morphology, using machine learning techniques.Methods and Results: Five hundred and nine AF patients underwent first ablation treatment in three centers were included and were followed‐up for postablative recurrent atrial arrhythmias. Data from 369 patients were regarded as training set, while data from another 140 patients, collected from different centers, were used as validation set. We manually measured 57 morphological parameters on enhanced computed tomography with three‐dimensional reconstruction technique and implemented unsupervised learning accordingly. Three morphological groups were identified, with distinct prognosis according to Kaplan−Meier estimator (p < .001). Multivariable Cox model revealed that morphological grouping were independent predictors of 1‐year recurrence (Group 1: HR = 3.00, 95% CI: 1.51−5.95, p = .002; Group 2: HR = 4.68, 95% CI: 2.40−9.11, p < .001; Group 3 as reference). Furthermore, external validation consistently demonstrated our findings.Conclusions: Our study illustrated the feasibility of employing unsupervised learning for the classification of LA morphology. By utilizing morphological grouping, we can effectively identify individuals at different risks of postablative recurrence and thereby assist in clinical decision‐making.
- Open Access
- 9 August 2023
- Published by Elsevier in Stem Cell Research
- Vol. 71, 103182
An integration-free iPSC line ZZUNEUi029-A derived from peripheral blood mononuclear cells of a patient with familial hypercholesterolemia carrying a mutation in LDLR gene
- 9 August 2023
- Published by Elsevier in Stem Cell Research
- Vol. 71, 103182
Open AccessAn integration-free iPSC line ZZUNEUi029-A derived from peripheral blood mononuclear cells of a patient with familial hypercholesterolemia carrying a mutation in LDLR gene
- Open Access
- 14 June 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (6) , e898
IL‐38 attenuates myocardial ischemia–reperfusion injury by inhibiting macrophage inflammation
Background: Reperfusion therapy is the most effective approach to resolve coronary occlusion, but myocardial injury caused by excessive inflammation during myocardial ischemia–reperfusion will also pose a new threat to health. Our prior study revealed the expression pattern of interleukin‐38 (IL‐38) in the peripheral blood serum of patients with ischemic cardiomyopathy and the role of IL‐38 in acute myocardial infarction in mice. However, its role and potential mechanisms in myocardial ischemia/reperfusion injury (MIRI) remain to be determined.Methods and Results: The left anterior descending artery of C57BL/6 mice was transiently ligated to induce the MIRI model. We found that MIRI induced the expression of endogenous IL‐38, which was mainly produced by locally infiltrating macrophages. Overexpression of IL‐38 in C57BL/6 mice attenuated inflammatory injury and decreased myocardial apoptosis after myocardial ischemia–reperfusion. Furthermore, IL‐38 inhibited lipopolysaccharide‐induced macrophage inflammation in vitro. Cardiomyocytes cocultured with the supernatant of IL‐38‐ and troponin I‐treated macrophages showed a lower rate of apoptosis than controls.Conclusions: IL‐38 attenuates MIRI by inhibiting macrophage inflammation. This inhibitory effect may be partially achieved by inhibiting the activation of NOD‐like receptor pyrin domain‐related protein 3 inflammasome, resulting in decreased expression of inflammatory factors and reduced cardiomyocyte apoptosis.
- 14 June 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (6) , e898
Open AccessIL‐38 attenuates myocardial ischemia–reperfusion injury by inhibiting macrophage inflammation
Background: Reperfusion therapy is the most effective approach to resolve coronary occlusion, but myocardial injury caused by excessive inflammation during myocardial ischemia–reperfusion will also pose a new threat to health. Our prior study revealed the expression pattern of interleukin‐38 (IL‐38) in the peripheral blood serum of patients with ischemic cardiomyopathy and the role of IL‐38 in acute myocardial infarction in mice. However, its role and potential mechanisms in myocardial ischemia/reperfusion injury (MIRI) remain to be determined.Methods and Results: The left anterior descending artery of C57BL/6 mice was transiently ligated to induce the MIRI model. We found that MIRI induced the expression of endogenous IL‐38, which was mainly produced by locally infiltrating macrophages. Overexpression of IL‐38 in C57BL/6 mice attenuated inflammatory injury and decreased myocardial apoptosis after myocardial ischemia–reperfusion. Furthermore, IL‐38 inhibited lipopolysaccharide‐induced macrophage inflammation in vitro. Cardiomyocytes cocultured with the supernatant of IL‐38‐ and troponin I‐treated macrophages showed a lower rate of apoptosis than controls.Conclusions: IL‐38 attenuates MIRI by inhibiting macrophage inflammation. This inhibitory effect may be partially achieved by inhibiting the activation of NOD‐like receptor pyrin domain‐related protein 3 inflammasome, resulting in decreased expression of inflammatory factors and reduced cardiomyocyte apoptosis.
- Open Access
- 1 January 2023
- Published by Wiley in Computational and Mathematical Methods in Medicine
- Vol. 2023 (1)
Clinical Outcomes and Predictors of Late Recurrence in Young Patients with Atrial Fibrillation after Catheter Ablation
Background. Catheter ablation (CA) is an established treatment for atrial fibrillation (AF), but the recurrence of AF is not neglected. Young patients with AF were generally more symptomatic and intolerant to long‐term drug treatment. We aim to explore clinical outcomes and predictors of late recurrence (LR) in AF patients younger than 45 years after CA to better manage them. Methods. We retrospectively studied 92 symptomatic AF patients who accepted CA from September 1, 2019, to August 31, 2021. Baseline clinical data (including N‐terminal prohormone of brain natriuretic peptide, NT‐proBNP), ablation outcomes, and follow‐up outcomes were collected. Patients were followed up at 3, 6, 9, and 12 months. Follow‐up data were available for 82/92 (89.1%) patients. Results. One‐year arrhythmia‐free survival was 81.7% (67/82) in our study group. Major complications occurred in 3/82 (3.7%) patients with an acceptable rate. The value of ln(NT‐proBNP) (P = 0.025, odds ratio [OR] = 1.977, 95% confidence interval [CI] 1.087‐3.596) and a family history of AF (P = 0.041, HR = 9.269, 95% CI 1.097‐78.295) could independently predict AF recurrence. The ROC analysis of ln(NT‐proBNP) showed that NT‐proBNP greater than 200.05 pg/ml (area under the curve: 0.772, 95% CI 0.642‐0.902, P = 0.001, sensitivity 0.800, specificity 0.701) was the cut‐off point for predicting late recurrence. Conclusions. CA is a safe and effective treatment for AF patients younger than 45 years. Elevated NT‐proBNP level and a family history of AF could be used as predictors for late recurrence in young patients. The result of this study may help us take more comprehensive management of those with high‐recurrence risks to reduce disease burden and improve quality of life.
- 1 January 2023
- Published by Wiley in Computational and Mathematical Methods in Medicine
- Vol. 2023 (1)
Open AccessClinical Outcomes and Predictors of Late Recurrence in Young Patients with Atrial Fibrillation after Catheter Ablation
Background. Catheter ablation (CA) is an established treatment for atrial fibrillation (AF), but the recurrence of AF is not neglected. Young patients with AF were generally more symptomatic and intolerant to long‐term drug treatment. We aim to explore clinical outcomes and predictors of late recurrence (LR) in AF patients younger than 45 years after CA to better manage them. Methods. We retrospectively studied 92 symptomatic AF patients who accepted CA from September 1, 2019, to August 31, 2021. Baseline clinical data (including N‐terminal prohormone of brain natriuretic peptide, NT‐proBNP), ablation outcomes, and follow‐up outcomes were collected. Patients were followed up at 3, 6, 9, and 12 months. Follow‐up data were available for 82/92 (89.1%) patients. Results. One‐year arrhythmia‐free survival was 81.7% (67/82) in our study group. Major complications occurred in 3/82 (3.7%) patients with an acceptable rate. The value of ln(NT‐proBNP) (P = 0.025, odds ratio [OR] = 1.977, 95% confidence interval [CI] 1.087‐3.596) and a family history of AF (P = 0.041, HR = 9.269, 95% CI 1.097‐78.295) could independently predict AF recurrence. The ROC analysis of ln(NT‐proBNP) showed that NT‐proBNP greater than 200.05 pg/ml (area under the curve: 0.772, 95% CI 0.642‐0.902, P = 0.001, sensitivity 0.800, specificity 0.701) was the cut‐off point for predicting late recurrence. Conclusions. CA is a safe and effective treatment for AF patients younger than 45 years. Elevated NT‐proBNP level and a family history of AF could be used as predictors for late recurrence in young patients. The result of this study may help us take more comprehensive management of those with high‐recurrence risks to reduce disease burden and improve quality of life.